What are the recommendations for using Tirzepatide (a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist) in patients with type 2 diabetes who are at risk of or have diabetic retinopathy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 4, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Tirzepatide and Diabetic Retinopathy: Clinical Recommendations

Primary Recommendation

Tirzepatide can be used in patients with type 2 diabetes at risk for diabetic retinopathy, but requires close ophthalmologic monitoring in those with established retinopathy, particularly patients with mild non-proliferative diabetic retinopathy (NPDR) with maculopathy or moderate-to-severe NPDR, as these patients face significantly increased risk of progression to proliferative diabetic retinopathy (PDR). 1

Risk Stratification and Patient Selection

Patients at Lower Risk (Can Initiate Tirzepatide with Standard Monitoring)

  • No diabetic retinopathy (R0M0): Tirzepatide is associated with reduced odds of new-onset retinopathy (OR 0.73,95% CI 0.62-0.86) in patients without baseline diabetic retinopathy. 1

  • Type 2 diabetes duration <10 years with no retinopathy: These patients have lower baseline risk and may benefit from tirzepatide's superior glycemic control (HbA1c reductions of 1.87-2.59%) without substantial retinopathy concerns. 2, 3

Patients at Higher Risk (Require Enhanced Monitoring)

  • Mild NPDR with maculopathy (R1M1): Tirzepatide significantly increases odds of progression to PDR in this population, warranting specialist ophthalmologist referral by ETDRS criteria. 1

  • Moderate-to-severe NPDR (R2M0, R2M1): These patients experienced significantly increased odds of incident PDR with tirzepatide therapy. 1

  • Diabetes duration ≥10 years: The 2024 ADA guidelines recommend close monitoring of retinopathy in older individuals with longer diabetes duration when using GLP-1 receptor agonists. 2

Pre-Treatment Ophthalmologic Assessment

Before initiating tirzepatide, obtain comprehensive retinal evaluation including:

  • Dilated fundoscopic examination by ophthalmologist or optometrist to establish baseline retinopathy status (R0-R3, M0-M1 grading). 2

  • Document specific retinopathy grade, as this determines monitoring intensity and progression risk. 1

  • Assess for proliferative changes, macular edema, and other high-risk characteristics. 2

Monitoring Protocol Based on Retinopathy Status

No Retinopathy at Baseline (R0M0)

  • Initial dilated eye examination at time of tirzepatide initiation. 2

  • Repeat examination annually if glycemic indicators remain within goal range. 2

  • Consider screening every 1-2 years if no retinopathy develops after first annual exam. 2

Mild NPDR Without Maculopathy (R1M0)

  • Dilated retinal examination at least annually. 2

  • Monitor for progression, particularly during first 6-12 months of tirzepatide therapy when rapid HbA1c reduction occurs. 2

Mild NPDR With Maculopathy (R1M1) or Moderate-to-Severe NPDR (R2M0, R2M1)

  • Refer to specialist ophthalmologist before initiating tirzepatide. 1

  • Dilated retinal examination every 3-6 months during first year of therapy. 2

  • More frequent examinations if retinopathy shows signs of progression. 2

  • Consider alternative glucose-lowering agents if retinopathy is rapidly progressing. 2

Proliferative Diabetic Retinopathy (R3M0, R3M1)

  • Exercise extreme caution with tirzepatide initiation. New-onset PDR occurred in 1.1% of tirzepatide-exposed individuals versus 0.5% of unexposed individuals (OR 2.15,95% CI 1.24-3.74). 1

  • Mandatory specialist ophthalmologist co-management. 2

  • Consider slower HbA1c reduction to minimize early worsening phenomenon. 2

  • Examinations required more frequently than annually based on ophthalmologist recommendation. 2

Mechanism of Retinopathy Risk

Early Worsening Phenomenon

  • Rapid reductions in HbA1c can be associated with initial worsening of retinopathy, a phenomenon observed with GLP-1 receptor agonists including liraglutide, semaglutide, and dulaglutide. 2

  • Tirzepatide produces unprecedented HbA1c reductions (1.24-2.58%), which may trigger this early worsening effect in susceptible patients. 3

  • The mechanism likely involves rapid changes in retinal blood flow and vascular permeability associated with acute glycemic improvement. 2

Risk Factors for Progression

  • Baseline retinopathy status is the strongest predictor, with mild NPDR with maculopathy (R1M1) and moderate-to-severe NPDR (R2M0, R2M1) showing highest progression risk. 1

  • Longer diabetes duration (≥10 years) increases vulnerability to retinopathy worsening. 2

  • Magnitude of HbA1c reduction correlates with retinopathy risk in GLP-1 receptor agonist trials. 2

Clinical Decision Algorithm

Step 1: Assess Baseline Retinopathy Status

  • Obtain dilated retinal examination before tirzepatide initiation. 2
  • Grade retinopathy using standardized classification (R0-R3, M0-M1). 1

Step 2: Risk-Stratify Patient

  • Low risk: No retinopathy (R0M0) → Proceed with tirzepatide, annual eye exams. 2, 1
  • Moderate risk: Mild NPDR without maculopathy (R1M0) → Proceed with tirzepatide, annual eye exams with close monitoring. 2
  • High risk: R1M1, R2M0, R2M1 → Ophthalmology referral before initiation, consider alternative agents. 1
  • Very high risk: PDR (R3M0, R3M1) → Mandatory ophthalmology co-management, consider alternative agents. 1

Step 3: Weigh Benefits vs. Risks

  • Favor tirzepatide when: Superior glycemic control needed (HbA1c >9%), significant obesity (BMI ≥35), cardiovascular disease present, no or minimal retinopathy. 2, 3
  • Consider alternatives when: Established moderate-to-severe retinopathy, rapid HbA1c reduction anticipated, patient unable to comply with frequent ophthalmologic monitoring. 1

Step 4: Implement Monitoring Plan

  • Schedule ophthalmologic follow-up based on retinopathy grade (see monitoring protocol above). 2
  • Assess retinopathy status when intensifying glucose-lowering therapies. 2

Alternative Considerations

When to Choose Alternative GLP-1 Receptor Agonists

  • Semaglutide 1.0 mg weekly: Provides substantial HbA1c reduction (approximately 1.4-1.48%) with proven cardiovascular benefit (26% reduction in MACE), though also associated with retinopathy worsening risk. 2, 4

  • Dulaglutide: Associated with increased risk of rapidly worsening diabetic retinopathy in randomized trials, similar concern as semaglutide. 2

  • Liraglutide: Also associated with retinopathy worsening risk in trials. 2

When to Choose Non-Incretin Agents

  • SGLT2 inhibitors: Provide cardiovascular and renal benefits without retinopathy worsening concerns; consider canagliflozin, empagliflozin, or dapagliflozin for patients with moderate-to-severe retinopathy. 2

  • Pioglitazone: May provide potential retinopathy benefit, though carries fluid retention and heart failure risks. 2

  • Basal insulin with gradual titration: Allows slower HbA1c reduction to minimize early worsening phenomenon. 2

Critical Pitfalls to Avoid

  • Do not initiate tirzepatide without baseline retinal examination in patients with diabetes duration ≥5 years or any known retinopathy. 2

  • Do not assume tirzepatide is safer than other GLP-1 receptor agonists regarding retinopathy—emerging evidence suggests similar or potentially greater risk in susceptible populations. 1

  • Do not delay ophthalmology referral in patients with R1M1, R2M0, R2M1, or R3 retinopathy grades when considering tirzepatide. 1

  • Do not ignore the early worsening phenomenon—patients with established retinopathy require more frequent monitoring during first 6-12 months of therapy. 2

  • Do not prioritize weight loss over vision preservation—in patients with advanced retinopathy, alternative glucose-lowering strategies may be more appropriate despite tirzepatide's superior weight loss efficacy (20.9% at 72 weeks). 4, 3

Balancing Benefits and Risks

Substantial Benefits of Tirzepatide

  • Unprecedented HbA1c reductions (1.24-2.58%) with 23.0-62.4% of patients achieving HbA1c <5.7%. 3

  • Superior weight loss (20.9% at 72 weeks with 15 mg dose) compared to semaglutide (14.9%). 4

  • Cardiovascular safety demonstrated with MACE-4 hazard ratios <1.0 and upper confidence bounds <1.3. 3

  • Improved insulin sensitivity and secretion beyond GLP-1 receptor agonists alone. 3

Retinopathy-Specific Risks

  • Increased odds of new-onset PDR (OR 2.15,95% CI 1.24-3.74) in tirzepatide-exposed individuals. 1

  • Highest risk in patients with mild NPDR with maculopathy (R1M1) or moderate-to-severe NPDR (R2M0, R2M1). 1

  • Risk appears related to rapid glycemic improvement rather than direct drug toxicity. 2

Clinical Context

  • In patients without retinopathy or with minimal retinopathy (R0M0, R1M0), tirzepatide's metabolic benefits substantially outweigh retinopathy risks with appropriate monitoring. 1

  • In patients with moderate-to-severe retinopathy, individualized risk-benefit assessment with ophthalmology input is essential before proceeding. 1

References

2
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

4
Guideline

Pharmacological Management of Obesity

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

Can a patient with elevated Serum Glutamic-Pyruvic Transaminase (SGPT) levels be started on tirzepatide (a dual Glucose-dependent Insulinotropic Polypeptide (GIP) and Glucagon-like peptide-1 (GLP-1) receptor agonist)?
What is the difference between Tirzepatide (dual GIP and GLP-1 receptor agonist) and Zepbound (tirzepatide)?
What is the equivalent dose of tirzepatide (dual GIP and GLP-1 receptor agonist) for a patient taking 1 mg of Ozempic (semaglutide) weekly?
What next steps should be taken for a patient with uncontrolled sugar levels and significant weight gain despite medication adjustments, including an increase in tirzepatide (GLP-1 receptor agonist) to 7.5mg?
How can I manage glucose spikes followed by hypoglycemia while on tirzepatide (GLP-1 and GIP receptor agonist)?
What is the recommended post-operative rehabilitation protocol for a patient with a clavicle fracture treated with plate fixation?
Can mirtazapine slow down metabolism, particularly in individuals with a history of weight gain or metabolic disorders?
How does calcium chloride affect blood pressure in patients post coronary artery bypass grafting (CABG) with a history of hypertension?
What is the likely diagnosis and next step for an adult patient with a history of infections or inflammatory conditions, who developed a bilateral rash in the center of the chest after being prescribed a Z-pack (azithromycin) and a Medrol Pak (methylprednisolone), which improved with triamcinolone but still persists?
What is the treatment for an L1-L2 transverse process fracture?
What are the treatment options for a patient presenting with cluster headaches?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question